ChemoCentryx Reports Results of FDA Meeting on Avacopan | #site_titleChemoCentryx Reports Results of FDA Meeting on Avacopan
Posted on 2969 ChemoCentryx, Inc. (NASDAQ: CCXI)reported the outcome of the United States Food and Drug Administration Arthritis Advisory Committee on avacopan to treat Antineutrophil Cytoplasmic Autoantibody associated vasculitis. In the final segment of the meetingthe committee voted on three questions present by the FDA: -The Committee vote split 9-9 on the first question, whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV (granulomatosis with polyangiitis (GPA) and microscopic ...